Genentech, a member of the Roche Group, announced that the phase III IMvigor211 study that evaluated Tecentriq (atezolizumab) in people with locally advanced or metastatic urothelial cancer whose disease progressed during or after treatment with a platinum-based chemotherapy did not meet its primary endpoint of overall survival compared to chemotherapy.
The Association of Community Cancer Centers has established a new e-course, Implementing Shared Decision-Making in Bladder Cancer Care, as part of its resources for cancer care centers to access evidence-based health literacy principles and shared decision-making strategies to reduce disparities in bladder cancer care.
